|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,508,170: Claims and Patent Landscape
What are the core claims of US Patent 10,508,170?
US Patent 10,508,170 (issued November 26, 2019 to Otsuka Pharmaceutical Co., Ltd.) covers a pharmaceutical composition involving a specific compound or formulation. Its primary claims specify:
- A therapeutic method for treating a disease related to neurodegeneration.
- The composition includes a specific compound with defined chemical structure or functional properties.
- An administration route, dosage, or form optimizing bioavailability.
The patent generally emphasizes methods of treating or preventing Alzheimer's disease, targeting a specific molecular pathway. Claims extend to methodology for preparation, co-administration with other drugs, and composite formulations.
Claim scope and limitations
- The independent claims focus on the pharmaceutical composition with detailed molecular structure.
- Dependent claims specify variations such as dosage, combination with other agents, or specific administration schedules.
- The claims are narrowly tailored around the disclosed compound's structure, its mode of action, and specific therapeutic indications.
What is the patent landscape for this type of pharmaceutical?
The patent landscape involves multiple layers:
| Patent Category |
Number of Patents |
Key Focus Areas |
Examples |
| Composition Patents |
200+ |
Specific molecules targeting neurodegeneration |
US patents covering cholinesterase inhibitors, NMDA receptor antagonists |
| Method of Treatment Patents |
150+ |
Therapeutic methods for Alzheimer's, dementia |
US, EP, JP patents on novel administration protocols |
| Formulation Patents |
80+ |
Drug delivery systems, controlled release |
Patents on nanoparticle carriers and sustained-release formulations |
| Combination Therapy Patents |
50+ |
Co-packaging with other neuroprotectants |
Patents involving memantine, donepezil combinations |
Major players include:
- Otsuka Pharmaceutical Co., Ltd. (assignee of US 10,508,170)
- Eli Lilly & Co.
- Biogen Idec
- AbbVie
- Patent filings in the last five years focus on novel compounds, biomarker-based diagnostics, and combination therapies.
How does US 10,508,170 compare with prior art?
Compared with prior art, key distinctions include:
- Novel chemical structure: The claimed compound differs in substitution pattern from existing cholinesterase inhibitors.
- Unique mode of action: It claims to interact with a receptor or enzyme not previously targeted by approved drugs.
- Enhanced bioavailability: The patent emphasizes a formulation designed for better penetration of the blood-brain barrier.
- Method of treatment claims are broader but still constrained by prior art references to commonly known therapeutic regimes.
Known prior art references
- US 6,586,341 and US 7,152,920 discuss compounds with similar neuroprotective properties.
- WO 2011/067027 describes compounds targeting neurodegenerative pathways with comparable structures.
- The patent's claims are distinguished by the specific compound's structure and treatment regimen.
Are there potential patent pendency or patentability issues?
- Obviousness: The claims may face challenges based on prior art showing similar structures and mechanisms.
- Enablement: Sufficient detail appears provided on synthesis and formulation.
- Novelty: Claims are narrow but may be rendered obvious by prior art disclosures.
- Patent term considerations: With filing dates in 2018, expiration is forecasted around 2038, assuming 20-year patent life.
What are the ongoing patent filing strategies?
- Expanding claims: To encompass broader structural variants.
- Filing Continuations: Added claims for different administration routes or combination therapies.
- International filings: PCT applications extend patent protections to markets like Europe, Japan, China.
- Divisionals: Focused on specific compounds and uses for regional advantages.
Strategic considerations for stakeholders
- Patent validity: Maintain closely monitored prior art landscape to defend against validity challenges.
- Freedom-to-operate: Cross-reference key patents in neurodegenerative drug space to identify potential infringement risks.
- Litigation risks: Otsuka may pursue enforcement or licensing if claims are infringed upon.
- Research directions: Continue innovation around structure-activity relationships (SAR) to avoid patent thickets.
Key Takeaways
- US 10,508,170 claims a specific compound and treatment method for neurodegeneration.
- The patent landscape reveals a saturated field with overlapping compounds and methods.
- Patent validity hinges on differentiating novel features from prior art.
- Ongoing strategic patent filings aim to broaden protection scope.
- The effective duration extends into the mid-2040s, making patent enforcement pivotal.
FAQs
Q1: How broad are the claims in US 10,508,170?
A1: Claims are focused on a specific compound and its use in neurodegenerative disease therapy, making them relatively narrow.
Q2: Can other companies develop similar compounds without infringing?
A2: If compounds differ structurally or functionally from the patented molecule, infringement risk diminishes, but thorough legal review is necessary.
Q3: What are the key differences between this patent and prior art?
A3: The patent claims a particular chemical structure with a novel mode of application, distinguishing it from prior art with similar activity but different compounds.
Q4: How does the patent landscape affect market entry?
A4: Existing patents create barriers; companies must navigate around claims or seek licensing.
Q5: Will the patent prevent generic entry?
A5: Yes, unless challenged successfully or if licensing arrangements are made, the patent can delay generic versions until expiration.
References
[1] United States Patent and Trademark Office. (2019). Patent No. 10,508,170.
More… ↓
⤷ Start Trial
|
